CDR813

CDR813 is a first-in-class, highly potent and selective bispecific and bivalent antibody fragment-based T cell engager (TCE) developed by CDR-Life. It targets tumors expressing PRAME (preferentially expressed antigen in melanoma), a clinically validated pan-cancer antigen found in multiple solid tumors such as non-small cell lung cancer, endometrial cancer, melanoma, and ovarian cancer but not in normal tissue. CDR813 binds to a PRAME peptide presented on tumor cells by the HLA-A*02 complex and simultaneously engages the CD3 receptor on T-cells, redirecting T-cell cytotoxicity specifically toward PRAME-expressing tumor cells. The molecule is designed for patients with the HLA-A*02:01 genotype using CDR-Life’s proprietary M-gager platform technology. Preclinical data indicate best-in-class potential with high specificity, potency, favorable pharmacological properties, and manufacturability[1][5][6][8][9].